¿Te has sentido limitado al no contar con todas las herramientas necesarias para diagnosticar, estratificar el riesgo y dar un seguimiento completo a pacientes con leucemia? Más info: me-qr.com/HUtVmFBo [email protected] #Encuesta #Leucemias #Hematología #GTLA

A shout-out to my friend and colleague Fausto A. Rios Olais, whose work has just been published. A thorough investigation that confirms the association of uMRD with PFS in first-line and r/r disease. jamanetwork.com/journals/jamao…

So proud of my friend Fausto A. Rios Olais. Take a look at this great article with important data about MRD and its impact on CLL. jamanetwork.com/journals/jamao…

So proud of my friend. Congrats Sergio Rodríguez-Rodriguez, MD, MSc. 🇲🇽 !

AML is the leading cause of alloHCT globally. Yet resource-limited countries still have a low transplant rate and a predisposition for related donors. Mexico is not the exception. Come find out how Rubens⚡️ delves into this issue in his latest paper. link.springer.com/article/10.100…

So glad to see the results of PI regimens implementation in our country by Roberta Demichelis. Important data that encourages ALL research in LATAM Society of Hematologic Oncology (SOHO).

Transient elastography is not a predictor of hepatotoxicity in ALL adults undergoing asparaginase-based therapy ⁦Roberta Demichelis⁩ ⁦@G_Rosales1⁩ Juan Luis Ontiveros, MD⁩ - meet us at poster ALL-343 ⁦Society of Hematologic Oncology (SOHO)⁩ clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

40 yo male with 33% BM blasts expressing CD7/CD33/CD34/CD117, with dim cCD3 coexpression of 24%, w/o expression of B-cell Ags, MPO, HLA-DR and CD13, CD2, CD4, CD5, CD8, and monocyte markers (CD14, CD16 and CD64)

#Guadalajara #Zapopan #mascotas #gato #gatito

Congratulations to Fausto A. Rios Olais, whose work is mentioned here. I am proud of my fellows! Dirección de Enseñanza del INCMNSZ HEM ONC INCMNSZ

So proud of my mentor Roberta Demichelis speaking about our country's limitations for leukemia diagnosis. The first step for improvement is knowing our problems. #ASH24 AMEH A.C. ASH

There's a lot to learn from pediatric hematologists about treating AYAs. Great abstracts that encourage adapted treatments in our patients. #ASH24

Come visit this great abstract session coordinated by my mentor Roberta Demichelis. Very interesting topics for improving our ALL outcomes. #ASH24 AMEH A.C. ASH

Today we had the visit of Doctor Rahul Purwar and Dr Hasmukh Jain from the TATA Institute and immunoACT who shared their experience of “Make-in-India” first CART therapy. We hope that this could become a reality for Mexican patients INCMNSZ Roberta Demichelis Crispín-Rosetti Lab

1/ Rituximab in ALL: What we know For Ph-neg B-ALL, rituximab has shown clear benefits: 🩺 Improved EFS (in trials like GRAALL-2005) 🩺 Enhanced outcomes, esp with ≥8 doses But for Ph-pos B-ALL evidence is lacking, as most trials exclude these patients

So proud of being part of this project.

🔬 ¡Lanzamos un nuevo proyecto de leucemia linfoblástica aguda (LLA)! 🌎💉 Si tratas adultos con LLA en LATAM, te invitamos a participar completando nuestro formulario. 🔗 docs.google.com/forms/d/e/1FAI… Tu aporte será clave para mejorar la atención de LLA en la región.

📢 Body composition in adult ALL 📊 In our study published at ESPEN, CT-assessed muscle mass & adiposity (visceral & subcutaneous) were linked to worse survival & more infections. clinicalnutritionespen.com/article/S2405-… Roberta Demichelis Fernando Gil-Lopez Analy Mora Jessica Zalapa

📝 A retrospective analysis published in Leukemia & Lymphoma found that the median OS was not reached in patients with Ph+ B-ALL receiving rituximab vs 14 months in those who did not. More news: lymphoblastic-hub.com #allsm #leusm #MedNews #MedEd

🚨 New Study Alert! 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM Arjun D. Law Ivan Pasic Our team retrospectively analyzed our cohort on allogeneic HSCT outcomes in patients with MDS/MPN overlap syndromes—a rare and challenging group of hematologic neoplasms. 🧵👇